2013-03-01
Exploring pharmacodynamics of immunosuppresive agents in transplantation
Publication
Publication
Meten van de biologische effecten van immunosuppressieve medicijnen bij transplantatiepatiënten
Supported by advancements in technology, surgical techniques and immunosuppressive drugs, solid organ transplantation has become the preferred solution to end stage organ failure. The first solid organ transplantation was performed in 1954 under supervision of Joseph Murray in the Peter Bent Brigham Hospital in Boston. A kidney from a healthy donor was transplanted into his identical twin, who suffered from chronic glomerulonephritis. The transplanted organ functioned immediately and the recipient survived for 25 years while the donor lived for another 56 years. Since the twins were genetically identical, no suppression of the immune system was needed. Transplantation between individuals other than identical twins was made possible a decade later by the use of the combination of azathioprine and corticosteroids, achieving a 1 year allograft1 survival rate of 40 to 50 percent.
| Additional Metadata | |
|---|---|
| , , | |
| Astellas Pharma, Becton Dickinson, Nederlandse Transplantatie Vereniging, Novartis Pharma, Pfizer Inc., Sanofi-Aventis, Shimadzu Pharma, Tebu-Bio Labaratories | |
| W. Weimar (Willem) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/38996 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Vafadari, R. (2013, March). Exploring pharmacodynamics of immunosuppresive agents in transplantation. Retrieved from http://hdl.handle.net/1765/38996 |
|
